
EHA2022 Hybrid Congress

CURRENT COMPLEXITIES, NEW APPROACHES IN THE TREATMENT OF MULTIPLE MYELOMA

Chaired by Professor Michele Cavo

Thursday, 9 June, 2022 19:15-20:45 CEST Attend in person—Hall A7 Join remotely—Virtual Room 2 on the EHA2022 Hybrid Congress platform



Programme

Introduction: Moving towards a new treatment paradigm



Prof. Michele Cavo

Head of Seràgnoli Institute of Hematology, Professor of Hematology, Bologna University School of Medicine, Department of Experimental, Diagnostic and Specialty Medicine. *Bologna, Italy*

Risk-adapted strategy in the treatment of multiple myeloma (MM)



Prof. Noopur Raje

Professor of Medicine, Harvard Medical School, Director, Center for Multiple Myeloma Massachusetts General Hospital. Boston, MA, USA

Measuring outcomes in MM: The role of minimal residual disease (MRD)



Dr. Salomon Manier

Associate Professor of Medicine at Lille University, Department of Hematologic Malignancies. *Lille, France*

Emerging mechanisms of action (MOAs) in the treatment of MM



Prof. Michele Cavo

Head of Seràgnoli Institute of Hematology, Professor of Hematology, Bologna University School of Medicine, Department of Experimental, Diagnostic and Specialty Medicine. Bologna, Italy

Q&A and closing remarks

All Speakers

Please join us on **Thursday, 9 June, 2022 at 19:15 CEST, in person in Hall A7 or remotely in Virtual Room 2**, as we present new achievements in risk stratification, assessment and monitoring of treatment response, and the potential role of new mechanisms of action in addressing unmet needs for the treatment of multiple myeloma.

